SUMMARY

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling
• Didona et al (2021)¹ described a patient with lichen planus (LP) and long-standing, refractory ulcerative tongue lesions, and anti-bullous pemphigoid 180 (anti-BP180) immunoglobulin G (IgG) who was treated with TREMFYA.
  • Within 6 months of TREMFYA treatment, ulcerations dramatically improved, but anti-BP180 IgG antibodies remained stable.
• Ghiam et al (2020)² reported the case of a 63-year-old female with a history of psoriasis (PsO) and LP (which developed during treatment with ixekizumab) who was successfully treated with TREMFYA.
  • After 5 months of treatment with TREMFYA for PsO, the patient’s PsO was clear, and LP lesions had resolved with residual hyperpigmentation.
• Solimani et al (2019)³ evaluated the therapeutic targeting of interleukin-17 (IL-17) or IL-17⁺ T cells to improve LP.
  • One patient with chronic recalcitrant erosive and ulcerative LP of the tongue was treated with TREMFYA, and the oral lesions fully resolved by week 30.

CLINICAL DATA

Didona et al (2021)¹ described a patient with LP and long-standing, refractory ulcerative tongue lesions and anti-BP180 IgG who was treated with TREMFYA.

• The patient received TREMFYA 200 mg subcutaneously (SC) every month initially, followed by bimonthly treatment.
• Although the oral ulcerations dramatically improved within 6 months, anti-BP180 IgG antibodies remained stable (53-55 relative units [RU]/mL).

Ghiam et al (2020)² reported the case of a 63-year-old female with a history of PsO and LP (which developed during treatment with ixekizumab) who was successfully treated with TREMFYA.

• The patient had a 15-year history of PsO and presented with a pruritic rash (diffuse over the abdomen, upper/lower extremities, chest, back, and pelvis) that interfered with sleep.
• Prior to the onset of rash, the treatment for PsO consisted of ixekizumab for 9 months, while previous treatments included narrow band ultraviolet B (UVB) for a month and adalimumab for 6 months.
• On physical examination, PsO flare was ruled out due to the absence of scaling, erythema, or induration of affected skin areas.
• A punch biopsy of 1 lesion identified changes consistent with LP.
• Ixekizumab was discontinued, and topical treatments of triamcinolone acetonide 0.1% cream (for the body) and clobetasol 0.05% solution (for the scalp) were started.
• The patient experienced partial resolution of pruritus and skin lesions by 2 weeks; after 6 weeks, the patient’s skin had mostly cleared and pruritus had substantially diminished.
• TREMFYA was initiated to treat PsO, and after 5 months, the patient’s PsO was clear and LP lesions had resolved with residual hyperpigmentation.

Solimani et al (2019)³ evaluated the therapeutic targeting of IL-17 or IL-17⁺ T cells to improve LP. One patient with chronic recalcitrant erosive and ulcerative LP of the tongue was treated with TREMFYA.

• The patient treated with TREMFYA was a 72-year-old female with extensive clinical manifestations of LP and a disease duration of 5 years. Chronic recalcitrant ulcerations of the tongue were previously unresponsive to topical and systemic glucocorticoids.
• TREMFYA was administered under compassionate use at 100 mg SC at weeks 0 and 4 and every 2 months thereafter. Oral lesions were treated with rinsing solutions of local anesthetics and antiseptics.
• The oral lesions fully resolved by week 30.

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, DERWENT^® (and other resources, including internal/external databases) was conducted on 28 January 2026.